Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific acquires C.R. Bard’s electrophysiology business. European Council issues a progress report on device reforms. More news in brief.

You may also be interested in...



Startup InPress Reports First Clinical Data For Postpartum Hemorrhage Device

Data from 10 patients supports quick action to stop hemorrhages, the leading cause of perinatal maternal death. InPress Technologies hopes to launch an FDA trial later this year.

News Briefs: Medtronic’s First-Gen Artificial Pancreas Approved; CMS Removes Bariatric Surgery Requirements

FDA approves Medtronic’s MiniMed 530G system, making it the first system in the U.S. that can automatically suspend insulin delivery to people with diabetes. CMS removes bariatric surgery facility certification requirements. More news.

Protecting Device Innovation: An Interview With Tom Fogarty

Noted physician-entrepreneur Tom Fogarty has long been known for inventing breakthrough products. Here he discusses his recent efforts to protect the medical device innovation model, and corrects what he sees as serious flaws in its long-term viability, especially in the U.S.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel